Biotech Startups

Predictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.

1 investor

PredictXBio uses AI, machine learning, and bioinformatics pipelines to predict how pathogens respond to drugs and to model antimicrobial potency in silico, aiming to accelerate discovery of antimicrobials against antimicrobial resistance. Its tools serve drug developers by predicting future resistance mutations and testing therapeutic compounds computationally.

1 investor

PreDxion Bio develops a rapid saliva-based antigen test for detecting SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients, scalable using semiconductor fabrication processes. Its original technology, spun out of the University of Michigan, is a near real-time cytokine and biomarker detection platform for monitoring immune response in critically ill patients, including those undergoing CAR-T therapy.

1 investor

PreGen applies artificial intelligence to gene expression data to develop clinically validated prognostic and predictive molecular tests for cancer patients, starting with prostate cancer. Its tests run on standard PCR equipment with results delivered via a web platform, designed for decentralized deployment in emerging countries, with a focus on Latin America.

1 investor

Premark Pharma develops therapeutic candidates for ophthalmologic conditions including blepharitis and dry eye disease. The company is advancing clinical-stage programs through Phase 3 development.

1 investor

A healthcare-focused company spun out from Hamamatsu University School of Medicine that aims to develop disease treatments and save patients' lives through scientific innovation. The company also contributes to disaster preparedness and emergency medical response in the Hamamatsu region.

1 investor

PreView Medical develops AI-powered spectroscopy systems for prostate cancer detection and treatment. The company has created the ClariCore® Biopsy System to improve detection during biopsies and a focal therapy system for precise treatment of prostate cancer.

1 investor

Esopredict is a methylation-based risk-stratification test that quantifies DNA methylation of four genes (p16, RUNX3, HPP1, FBN1) combined with patient age to predict a patient's 5-year risk of progressing from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma. Offered by Castle as a companion to its TissueCypher test, it produces a risk score and risk level to help clinicians manage patients with non-dysplastic, indefinite, or low-grade Barrett's esophagus.

1 investor

PRIMACYT develops isolated liver cell models and toxicity testing services for medical device and pharmaceutical research. The company serves research institutions, universities, and industrial clients requiring preclinical safety assessment capabilities.

1 investor

Primal Therapies develops microbial biotechnology, including patented small molecule drugs and functional ingredients for biofilm management, infection control, and microbiome modulation. Its SMMRT platform targets metabolic receptors and enzymes in bacteria, viruses, and fungi to address antimicrobial resistance, disinfection, and chronic disease across healthcare and other industries.

1 investor

Primary Bioscience is developing a single-molecule protein sequencing device for comprehensive, multi-biomarker screening. The technology aims to sequence every protein in a sample, including hard-to-detect variations such as single residue substitutions, splice variants, and post-translational truncations.

1 investor

Primient is a producer of food and industrial ingredients derived from plant-based, renewable resources, serving customers in food, beverage, paper, packaging, personal care, apparel, and animal nutrition industries. The company operates production facilities and shared service centers globally, with a focus on sustainable plant-based innovation and bioeconomy solutions.

1 investor

Primitives is a biodesign lab that develops advanced biomaterials—including biopolymers, biominerals, and compostable packaging—aimed at ecosystem regeneration and emissions reduction. Its work spans biodegradable seaweed-based sensors, compostable food packaging that indicates food quality, and MARBLIS, an architectural surfaces brand producing engineered biomarble (biocalcite) from overpopulated or invasive species, serving non-profits, governments, industry, and research organizations.

1 investor

A precision-medicine company that uses radiochemistry and molecular imaging to develop and manufacture radioisotope-based diagnostic and therapeutic drugs, focused on hard-to-treat cancers. It also pursues drug-development partnerships built on its radioisotope platform technology.

1 investor

PrintBio manufactures 3D-printed bioresorbable surgical meshes designed for hernia repair and soft tissue support. The company serves surgeons and hospitals seeking customizable mesh solutions that combine stability and flexibility while reducing infection risk.

1 investor

PriZm Tx develops treatments for rare genetic disorders, with a focus on MCT8 Deficiency (AHDS), an ultra-rare condition affecting boys. Its lead candidate is a first-in-class therapy for this disorder.

1 investor

Promatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting. It is building a pipeline of cancer therapies with a lead program in colorectal cancer.

1 investor

ProAxsis provides biomarker analysis services and research assays for respiratory disease drug development, serving pharmaceutical, biotechnology, and academic research organizations.

1 investor

ProBioGen is a contract development and manufacturing organization (CDMO) that develops and manufactures biopharmaceuticals, viral vectors, and vaccines for biopharma clients. Its services cover cell line development, process development, GMP manufacturing, and analytical services for proteins, antibodies, viral vectors, and vaccines.

1 investor

ProBiotix Health develops probiotic formulations aimed at lifestyle conditions such as cardiometabolic health, backed by clinical trials conducted with UK universities and microbiology researchers. It collaborates with research institutes, universities, and hospitals across the UK and Europe to develop and validate its probiotic products.

1 investor

Procarta Biosystems develops gene control technology to treat drug-resistant bacterial infections, including MRSA. The company was spun out from the John Innes Centre and Plant Biosciences Limited and focuses on anti-infective therapeutics for the biotech and pharmaceutical sector.

1 investor

Procavea Biotech develops a protein-based molecular delivery platform (nonviral protein cages) to address delivery limitations in RNA therapeutics, with applications also in medical imaging. An ETH Zurich spin-off, it targets the pharmaceutical and biotech sector.

1 investor

ProciseDx develops diagnostic technology, including a point-of-care testing platform, drawing on expertise in central lab instrumentation and point-of-care devices. It serves the point-of-care diagnostics market.

1 investor

ProDigest operates advanced in vitro gut simulation platforms that help companies across industries develop superior products. The company specializes in microbial fermentation and gut microbiome research technologies.

1 investor